1st of October the Healthe-rnd consortium was finally able to meet again face-to-face in Prague. Most of the partners were able to attend despite the ongoing restrictions due to the pandemic. The ones who couldn’t make it to Prague attended on Zoom. It was great to see each other again and also meet new faces as…
Read more
EHDN Online Plenary Meeting 2021 – Having listened to the presentations about ongoing and upcoming clinical trials during the EHDN virtual conference has filled me with renewed enthusiasm and energy – Says Astri Arnesen, EHA President . We were all hit by the setbacks in Roche and Waves trials earlier this year. But during the…
Read more
An article by by Prof Åsa Petersèn and Sanaz Gabery This article is modified and translated from Lund University homepage, Agata Garpenlind. Our results demonstrate that parts of the brain that manage emotions, the so-called limbic system, is affected early in HD mutation carriers. These changes may contribute to the development of psychiatric and cognitive symptoms. …
Read more
Tomsk, July 10, 2021 The European Huntington Association is happy to announce the launch of the international project «Moving Forward» in Russia! The first city to present the project was Tomsk, which is situated in Syberia. 17 members of the HD families and several doctors-neurologists attended the interregional “School of Health”, organized by the center…
Read more
Results from Generation HD1 As you all remember in March the independent Data Monitoring Committee advised Roche to halt dosing of the drug Tominersen. On April 27 Scott Schobel, Medical Director & Clinical Science Leader at Roche shared the interim analyses of the results from the Generation HD1 at the CHDI therapeutics conference. Drug effect…
Read more
